nach oben

Erschienen in:

24.07.2021 | Original Article

Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries

verfasst von: Vassiliki Kotoula, Kyriaki Papadopoulou, Ioannis Tikas, Florentia Fostira, Eleni Vrettou, Sofia Chrisafi, Elena Fountzilas, Georgia-Angeliki Koliou, Paraskevi Apostolou, Konstantinos Papazisis, Thomas Zaramboukas, Anthoula Asimaki-Vlachopoulou, Spyros Miliaras, Ananias Ananiadis, Christos Poulios, Ioannis Natsiopoulos, Aris Tsiftsoglou, Efterpi Demiri, George Fountzilas

Erschienen in: Breast Cancer | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The genomic status of non-malignant tissues from carriers of pathogenic germline BRCA1/2 (gBRCA1/2) variants may reveal information towards individualized prophylaxis. We performed spatiotemporal tissue genotype comparisons in a real-life cohort of gBRCA1/2 carriers of Greek origin, who underwent multiple risk-reducing/prophylactic surgeries at various time points.

Methods

Fifty-three women (median age 36 years) within cancer families were observed for up to 37.5 years; 43 were cancer carriers and 10 were healthy carriers. Histology review and genotyping were performed for 187 paraffin tissues (average: 3.5 per carrier) including 46 carcinomas (40 breast) and 141 non-malignant breast and gynecological samples.

Results

High allelic imbalance (AI) and somatic pathogenic TP53 variants were present in cancer carriers only (p values < 0.0001). High AI was associated with gBRCA1/2 indels (p < 0.0001) and gBRCA2 alterations (p = 0.0109). Somatic (pathogenic) variants were infrequently shared between non-malignant tissues and matched carcinomas. Aberrations of gBRCA1 variant heterozygosity were noticed in tissues from cancer carriers only (13/43, 30.2%). These pertained to classic LOH (neoplastic lesions in 9/43 carriers, 20.9%) and under-representation of the germline variants (5 samples, 4 non-malignant, all in the breast). Both aberrations coexisted in matched samples in one case. Over time, germline variant heterozygosity prevailed in non-malignant tissues; intra-carrier genomic alterations were aggravated (21.1%), ameliorated (26.3%) or remained stable.

Conclusion

This real-life case study supports the need to address tissue genotypes from prophylactic surgeries in combination with polygenic scores towards personalized prophylaxis. To this end, knowing the traditionally classified pathogenic potential of a gBRCA1/2 variant may not be enough.

Nur mit Berechtigung zugänglich

Mau C, Untch M. Prophylactic surgery: for whom, when and how? Breast care. 2017;12(6):379–84.PubMedPubMedCentralCrossRef

Practice bulletin no. 182 summary: hereditary breast and ovarian cancer syndrome. Obstetr Gynecol. 2017;130(3):657–9.

NCCN. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, v.1.2020 2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed 2 July 2020.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc. 2010;304(9):967–75.CrossRef

Fayanju OM, Stoll CR, Fowler S, Colditz GA, Margenthaler JA. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014;260(6):1000–10.PubMedCrossRef

Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, et al. Contralateral Prophylactic Mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100–5.PubMedPubMedCentralCrossRef

Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8: CD012464.PubMed

Kotsopoulos J. BRCA mutations and breast cancer prevention. Cancers. 2018;10(12):524.PubMedCentralCrossRef

Domchek SM. Risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers: a complex discussion. JAMA. 2019;321(1):27.PubMedCrossRef

10.

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134–47.CrossRef

11.

Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347–61.PubMedPubMedCentralCrossRef

12.

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for brca1 and brca2 mutation carriers. JAMA. 2017;317(23):2402–16.PubMedCrossRef

13.

Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, et al. A response to “Personalised medicine and population health: breast and ovarian cancer.” Hum Genet. 2019;138(3):287–9.PubMedPubMedCentralCrossRef

14.

Venkitaraman AR. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? DNA Repair. 2019;81: 102668.PubMedPubMedCentralCrossRef

15.

Hatano Y, Tamada M, Matsuo M, Hara A. Molecular trajectory of BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:361.PubMedPubMedCentralCrossRef

16.

Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, et al. Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast. J Pathol. 1999;189(4):496–503.PubMedCrossRef

17.

Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosom Cancer. 2010;49(1):78–90.PubMedCrossRef

18.

Karaayvaz-Yildirim M, Silberman RE, Langenbucher A, Saladi SV, Ross KN, Zarcaro E, et al. Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers. Sci Adv. 2020;6(5): eaay2611.PubMedPubMedCentralCrossRef

19.

Konstantopoulou I, Tsitlaidou M, Fostira F, Pertesi M, Stavropoulou AV, Triantafyllidou O, et al. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. Clin Genet. 2014;85(1):36–42.PubMedCrossRef

20.

Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, et al. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation. Clin Genet. 2017;91(3):482–7.PubMedCrossRef

21.

Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, et al. Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: deep sequencing data from ovarian cancer patients. Gynecol Oncol. 2019;152(2):375–86.PubMedCrossRef

22.

Dubbink HJ, Atmodimedjo PN, van Marion R, Krol NMG, Riegman PHJ, Kros JM, et al. Diagnostic detection of allelic losses and imbalances by next-generation sequencing: 1p/19q co-deletion analysis of gliomas. J Mol Diagn. 2016;18(5):775–86.PubMedCrossRef

23.

Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, et al. High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. npj Genom Med. 2019;4(1):13.PubMedPubMedCentralCrossRef

24.

Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, et al. Influence of BRCA1 germline mutations in the somatic mutational burden of triple-negative breast cancer. Transl Oncol. 2019;12(11):1453–60.PubMedPubMedCentralCrossRef

25.

Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V, et al. Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat. 2004;88(2):131–9.PubMedCrossRef

26.

Danforth DN Jr. Genomic changes in normal breast tissue in women at normal risk or at high risk for breast cancer. Breast Cancer. 2016;10:109–46.PubMedPubMedCentral

27.

Palin K, Pitkanen E, Turunen M, Sahu B, Pihlajamaa P, Kivioja T, et al. Contribution of allelic imbalance to colorectal cancer. Nat Commun. 2018;9(1):3664.PubMedPubMedCentralCrossRef

28.

Risques RA, Kennedy SR. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14(1): e1007108.PubMedPubMedCentralCrossRef

29.

Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol. 2002;161(1):283–90.PubMedPubMedCentralCrossRef

30.

Chromosome instability drives tumor evolution. Cancer Discov. 2017;7(6):546. PMID:28487325

31.

Singh AK, Yu X. Tissue-specific carcinogens as soil to seed BRCA1/2-mutant hereditary cancers. Trends Cancer. 2020;6(7):559–68.PubMedCrossRef

32.

Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–13.PubMedPubMedCentralCrossRef

33.

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017;17(10):605–19.PubMedPubMedCentralCrossRef

34.

Singh AK, Yu X. Tissue-specific carcinogens as soil to seed BRCA1/2-mutant hereditary cancers. Trends Cancer. 2020;6:559–68.PubMedCrossRef

35.

Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, et al. Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol. 2020;4:442–65.PubMedCrossRef

36.

Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, et al. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer. 2009;101(1):32–7.PubMedPubMedCentralCrossRef

37.

Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, et al. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet. 2020;57(1):53–61.PubMedCrossRef

38.

LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407–15.PubMedCrossRef

39.

Kachuri L, Graff RE, Smith-Byrne K, Meyers TJ, Rashkin SR, Ziv E, et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat Commun. 2020;11(1):6084.PubMedPubMedCentralCrossRef

40.

Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020;22(10):1653–66.PubMedPubMedCentralCrossRef

41.

Semmler L, Reiter-Brennan C, Klein A. BRCA1 and breast cancer: a review of the underlying mechanisms resulting in the tissue-specific tumorigenesis in mutation carriers. J Breast Cancer. 2019;22(1):1–14.PubMedPubMedCentralCrossRef

42.

Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, et al. Association of a polygenic risk score with breast cancer among women carriers of high- and moderate-risk breast cancer genes. JAMA Netw Open. 2020;3(7): e208501.PubMedPubMedCentralCrossRef

43.

Narod SA. Personalised medicine and population health: breast and ovarian cancer. Hum Genet. 2018;137(10):769–78.PubMedCrossRef

44.

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25.PubMedPubMedCentralCrossRef

45.

Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8(1):319.PubMedPubMedCentralCrossRef

46.

Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49(10):1476–86.PubMedPubMedCentralCrossRef

47.

Nguyen L, Martens JWM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584.PubMedPubMedCentralCrossRef

48.

Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet. 2003;40(10):721–8.PubMedPubMedCentralCrossRef

49.

May M. Mutations to the rescue. Nat Med. 2011;17(4):405–7.PubMedCrossRef

50.

Ganesan S. Tumor suppressor tolerance: reversion mutations in BRCA1 and BRCA2 and resistance to PARP inhibitors and platinum. JCO Precis Oncol. 2018;2:1–4.PubMed

51.

Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020;10(10):1475–88.PubMedPubMedCentralCrossRef

52.

Tobalina L, Armenia J, Irving E, O’Connor MJ, Forment JV. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32(1):103–12.PubMedCrossRef

53.

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy099.CrossRefPubMedPubMedCentral

54.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, et al. Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition. J Clin Oncol. 2017;35(11):1240–9.PubMedCrossRef

55.

Jacob SL, Kiedrowski LA, Chae YK. The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy. Heliyon. 2020;6(5): e03841.PubMedPubMedCentralCrossRef

Titel: Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries
verfasst von: Vassiliki Kotoula
Kyriaki Papadopoulou
Ioannis Tikas
Florentia Fostira
Eleni Vrettou
Sofia Chrisafi
Elena Fountzilas
Georgia-Angeliki Koliou
Paraskevi Apostolou
Konstantinos Papazisis
Thomas Zaramboukas
Anthoula Asimaki-Vlachopoulou
Spyros Miliaras
Ananias Ananiadis
Christos Poulios
Ioannis Natsiopoulos
Aris Tsiftsoglou
Efterpi Demiri
George Fountzilas
Publikationsdatum: 24.07.2021
Verlag: Springer Singapore
Erschienen in: Breast Cancer / Ausgabe 6/2021
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-021-01276-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?

Acknowledgments to reviewers 2021

New variant of breast-invasive lobular carcinoma with solid and encapsulated papillary carcinoma growth pattern

Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

The transverse musculocutaneous gracilis flap for autologous breast reconstruction: focus on donor site morbidity

Negative impact of the COVID-19 state of emergency on breast cancer screening participation in Japan

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie